Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

Cohort study: After an episode of severe hypoglycemia in older adults with diabetes, sulfonylurea or insulin treatment deintensification occurred in fewer than 50% of episodes.

12 Nov, 2021 | 09:53h | UTC

Deintensification of Treatment With Sulfonylurea and Insulin After Severe Hypoglycemia Among Older Adults With Diabetes – JAMA Network Open

 

Commentary on Twitter

 

Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis – “Each day of antibiotic therapy was associated with 4% increased odds of experiencing an adverse event”.

12 Nov, 2021 | 09:47h | UTC

Estimating daily antibiotic harms: an umbrella review with individual study meta-analysis – Clinical Microbiology and Infection

 

Commentary on Twitter

 

COVID antiviral pills: what scientists still want to know – “Drugs like Molnupiravir and Paxlovid could change the course of the pandemic if clinical trial results hold up in the real world”.

11 Nov, 2021 | 08:59h | UTC

COVID antiviral pills: what scientists still want to know – Nature

Related:

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

M-A: Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19.

11 Nov, 2021 | 08:53h | UTC

Low vitamin D levels do not aggravate COVID-19 risk or death, and vitamin D supplementation does not improve outcomes in hospitalized patients with COVID-19: a meta-analysis and GRADE assessment of cohort studies and RCTs – Nutritional Journal

 

RCT: In patients with acute myocardial infarction complicated by a reduced left ventricular ejection fraction, pulmonary congestion, or both, Sacubitril–valsartan was not associated with improved outcomes compared to Ramipril.

11 Nov, 2021 | 08:44h | UTC

Angiotensin Receptor–Neprilysin Inhibition in Acute Myocardial Infarction – New England Journal of Medicine (link to abstract – $ for full-text)

 

French health authority advises against Moderna Covid-19 vaccine for under 30s.

10 Nov, 2021 | 07:18h | UTC

French Health Authority Advises Against Moderna COVID-19 Vaccine for Under 30s – Reuters

See also: France advises against Moderna for under-30s over rare heart risk – Associated Press

Related: Sweden, Denmark pause Moderna COVID-19 vaccine for younger age groups.

 

Commentary on Twitter

 

A prominent virologist warns new COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm.

10 Nov, 2021 | 07:13h | UTC

A prominent virologist warns COVID-19 pill could unleash dangerous mutants. Others see little cause for alarm – Science

Original viewpoint: Supercharging New Viral Variants: The Dangers Of Molnupiravir (Part 1) – Forbes

Related:

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Large observational study suggests prolactin-increasing antipsychotics are associated with increased risk of breast cancer (OR=1.56 for over 5 years of exposure); prolactin-sparing antipsychotics (including clozapine, quetiapine, or aripiprazole), on the other hand, were not associated with increased risk.

10 Nov, 2021 | 06:57h | UTC

Antipsychotic use and risk of breast cancer in women with schizophrenia: a nationwide nested case-control study in Finland – The Lancet Psychiatry (link to abstract – $ for full-text)

Commentary: Choosing between antipsychotics to reduce the risk of breast cancer in women with schizophrenia – The Mental Elf

 

Commentary on Twitter

 

Cohort study: In utero exposure to 17α-hydroxyprogesterone caproate linked to increased risk of cancer in offspring.

10 Nov, 2021 | 06:59h | UTC

In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring – American Journal of Obstetrics and Gynecology (link to abstract – $ for full-text)

Commentary: Drug used to prevent miscarriage increases risk of cancer in offspring – The University of Texas Health Science Center at Houston

Related: Randomized Trial: Injectable 17-α-hydroxyprogesterone Not Effective for the Prevention of Recurrent Preterm Birth

 

How protein-based COVID vaccines could change the pandemic.

9 Nov, 2021 | 01:41h | UTC

How protein-based COVID vaccines could change the pandemic – Nature

 

Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccines.

9 Nov, 2021 | 01:31h | UTC

Nose sprays, needle-free patches, durable immunity: towards the next generation of COVID vaccines – The Conversation

 

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain.

9 Nov, 2021 | 01:17h | UTC

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain – Agency for Healthcare Research and Quality

See also:

Evidence Summary

Final Report

Related:

The International Cannabis Toolkit (iCannToolkit): a multidisciplinary expert consensus on minimum standards for measuring cannabis use.

Cannabis products are being sold as sleep remedies – here’s the evidence about their effectiveness.

Guideline: Medical cannabis or cannabinoids for chronic pain.

Cannabis and Cannabinoid Analgesia position statement – “Due to the lack of high-quality clinical evidence, the IASP does not currently endorse general use of cannabis and cannabinoids for pain relief.”

NICE Guideline: Cannabis-Based Medicinal Products

Consensus recommendations for perioperative management of cannabis and cannabinoid-based medicine users

Living Systematic Review on Cannabis and Other Plant-Based Treatments for Chronic Pain – Agency for Healthcare Research and Quality

Short Review: Drug Interactions with Cannabinoids

Meta-Analysis: Cannabinoids Not Effective for Cancer-Related Pain

 

[Press release – not published yet] RCT: Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study.

7 Nov, 2021 | 20:35h | UTC

Pfizer’s novel Covid-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR Study

Commentaries:

Expert reaction to press release from Pfizer giving interim analysis of their Phase 2/3 EPIC-HR study of PAXLOVID™ in non-hospitalized high-risk adults with COVID-19 – Science Media Centre

Pfizer’s Good News Is the World’s Good News – Science

Experimental Pfizer pill prevents Covid hospitalizations and deaths – STAT

Pfizer Says New Anti-Viral Drug Combination Cuts Risks Of Serious COVID-19 By 89% – Health Policy Watch

Pfizer reports good results against severe COVID-19 for its antiviral pill – CIDRAP

Covid: Pfizer says antiviral pill 89% effective in high-risk cases – BBC

Pfizer says COVID-19 pill cut hospital, death risk by 90% – Associated Press

Pfizer’s COVID-19 pill treatment reduces risk of being hospitalized or dying by 89%, company says – ABC News

 

Commentary on Twitter (thread – click for more)

 

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination.

7 Nov, 2021 | 20:29h | UTC

Myocarditis Following COVID-19 mRNA Vaccine: A Case Series and Incidence Rate Determination – Clinical Infectious Diseases

Related:

Heart-inflammation risk from Pfizer COVID vaccine is very low.

Large cohort study with over 2.5 million individuals showed the incidence of myocarditis after the Pfizer vaccine was 2.13 cases per 100,000 persons.

Study with over 5.1 million vaccinated individuals showed the incidence of myocarditis after the receipt of the Pfizer vaccine was low and more common after the second dose in young male recipients.

Large Observational study shows Pfizer Covid vaccine is mostly safe but is associated with increased risk of myocarditis, adenopathy, appendicitis, and herpes zoster.

 

Viewpoint | Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know.

7 Nov, 2021 | 20:31h | UTC

Pediatric COVID-19 Vaccines: What Parents, Practitioners, and Policy Makers Need to Know – JAMA

 

[Not published yet] Chinese drug firm Sinovac says Covid-19 vaccine safe for children and babies as young as six months old.

7 Nov, 2021 | 20:32h | UTC

Chinese drug firm Sinovac says Covid-19 vaccine safe for children, babies as young as six months old; submits data to Hong Kong government – South China Morning Post

Related:

Randomized phase 1/2 trial: Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in children and adolescents aged 3–17 years.

Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years.

 

COVID-19 vaccination in pregnancy, pediatrics, immunocompromised patients, and persons with history of allergy or prior SARS-CoV-2 infection: overview of current recommendations and pre- and post-marketing evidence for vaccine efficacy and safety.

7 Nov, 2021 | 20:27h | UTC

COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety – Drug Safety

 

RCT: In patients with chronic kidney diseases and anemia undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa to increase hemoglobin levels and regarding cardiovascular outcomes.

7 Nov, 2021 | 20:18h | UTC

Daprodustat for the Treatment of Anemia in Patients Undergoing Dialysis – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Oral pill as safe, efficacious as conventional treatment for anemia in patients with kidney disease – Brigham and Women’s Hospital

 

Commentary on Twitter

 

Germany offers booster shots to everyone amid ‘very worrying’ surge in cases.

7 Nov, 2021 | 20:22h | UTC

Germany offers booster shots to everyone amid ‘very worrying’ surge in cases – CNN

 

RCT: In patients with chronic kidney diseases and anemia not undergoing dialysis, Daprodustat (oral drug) was noninferior to darbepoetin alfa in increasing hemoglobin levels and regarding cardiovascular outcomes.

7 Nov, 2021 | 20:17h | UTC

Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis – New England Journal of Medicine (link to abstract – $ for full-text)

News Release: Oral pill as safe, efficacious as conventional treatment for anemia in patients with kidney disease – Brigham and Women’s Hospital

 

Commentary on Twitter

 

RCT: In patients with advanced chronic kidney disease and poorly controlled hypertension, Chlortalidone had a significant impact in blood-pressure control (−11.0 mm Hg vs. −0.5 mm Hg in the placebo group).

7 Nov, 2021 | 20:20h | UTC

Chlorthalidone for Hypertension in Advanced Chronic Kidney Disease – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Cheap Diuretic, Chlorthalidone, Drops BP in Advanced Kidney Disease – Medscape (free registration required)

 

Commentary on Twitter

 

Mapping conflict of interests: scoping review.

7 Nov, 2021 | 20:10h | UTC

Mapping conflict of interests: scoping review – The BMJ

Press release: Study reveals “extensive network” of industry ties with healthcare – BMJ

 

NICE draft guideline recommends SGLT2 inhibitor dapagliflozin for some patients with chronic kidney disease.

7 Nov, 2021 | 20:14h | UTC

NICE recommend dapagliflozin for people with chronic kidney disease – National Institute for Health and Care Excellence

See draft guideline:

Appraisal consultation document (online commenting)

Appraisal consultation document (PDF version)

Related:

NICE Guideline: Assessment and management of chronic kidney disease.

Secondary analysis of RCT finds Dapagliflozin is safe for patients with stage 4 chronic kidney disease.

Randomized trial: Dapagliflozin in patients with chronic kidney disease

 

Study compares the decline in effectiveness for Moderna, Pfizer, and Janssen vaccines and consequences for mortality.

5 Nov, 2021 | 09:59h | UTC

Original study: SARS-CoV-2 vaccine protection and deaths among US veterans during 2021 – Science

News release: Breakthrough Infection Study Compares Decline in Vaccine Effectiveness and Consequences for Mortality – Public Health Institute

 

Commentary on Twitter

 

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first.

5 Nov, 2021 | 09:51h | UTC

The U.K. approves Merck’s COVID-19 antiviral pill, calling it a world first – NPR

Related:

Merck to allow other nations to produce new COVID-19 antiviral.

Video: Merck’s Covid pill could transform treatment. Here’s how it works.

How antiviral pill Molnupiravir shot ahead in the COVID drug hunt.

What we know — and don’t know — about Merck’s new Covid-19 pill.

[Press release – not published yet] Merck announces oral antiviral Molnupiravir reduced the risk of hospitalization or death by approximately 50 Percent compared to placebo for patients with mild or moderate COVID-19.

Merck’s Covid-19 pill is great news but may not be a game-changer.

Video | A Pill For COVID? A Doctor Explains Molnupiravir.

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.